Physician profile
Christopher Cha
NPI 1871265959
$8,193.91
in general payments reported to CMS, 2019-2025
18 companies · $2,248 in 2025
The $2,248 reported for 2025 was more than what 97% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $105 · 2022: $354 · 2023: $2,467 · 2024: $3,020 · 2025: $2,248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,734.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,734.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,382.76 | 2022-2025 | Vuity, Durysta, Lumigan |
| Bausch & Lomb Americas INC. | $1,208.95 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Sun Pharmaceutical Industries INC. | $849.20 | 2023-2025 | Cequa |
| Rxsight INC | $810.31 | 2022-2025 | Rxsight Injector Handpiece, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Alcon Vision LLC | $763.97 | 2023-2025 | Tryptyr, Rocklatan, Eysuvis |
| Biotissue Holdings INC. | $603.40 | 2023-2025 | |
| Glaukos Corporation | $603.23 | 2024-2025 | Idosetr, Idose |
| Harrow Eye, LLC | $505.12 | 2024-2025 | Vevye |
| Tarsus Pharmaceuticals, INC. | $357.09 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $235.58 | 2023-2024 | Tyrvaya, Ryzumvi |
| Dompe US, INC. | $231.28 | 2023-2025 | Oxervate |
| Carl Zeiss Meditec USA, INC. | $172.52 | 2023-2024 | Cirrus Hd-Oct, Artevo 800, Humphrey Hfa |
| Apellis Pharmaceuticals, INC. | $114.30 | 2024 | Syfovre |
| Astellas Pharma US INC | $107.11 | 2023 | |
| Allergan, INC. | $105.27 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lensar, INC. | $54.95 | 2024 | Lensar Laser System |
| Thea Pharma INC. | $47.75 | 2023-2024 | Iyuzeh |
| Novartis Pharmaceuticals Corporation | $41.12 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Cha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.